
Zoltan Matrai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9146158/publications.pdf Version: 2024-02-01



ΖΟΙ ΤΑΝ ΜΑΤΡΑΙ

#	Article	IF	CITATIONS
1	Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia. Blood, 2002, 100, 1404-1409.	1.4	213
2	CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood, 2001, 97, 1902-1902.	1.4	74
3	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nature Communications, 2020, 11, 577.	12.8	69
4	B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia. Cancer Research, 2005, 65, 7328-7337.	0.9	54
5	CD38 as a prognostic marker in CLL. Hematology, 2005, 10, 39-46.	1.5	52
6	Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. International Journal of Cancer, 2020, 146, 85-93.	5.1	41
7	High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood, 2003, 102, 1145-1146.	1.4	38
8	JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia, 2010, 24, 1809-1813.	7.2	25
9	Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2016, 2, 847-849.	3.2	22
10	Correlation Between Cell Size and CD38 Expression in Chronic Lymphocytic Leukaemia. Leukemia and Lymphoma, 2003, 44, 797-800.	1.3	20
11	The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica, 2011, 96, 1613-1618.	3.5	17
12	Serum β2-microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults. Clinical Chemistry and Laboratory Medicine, 2009, 47, 585-9.	2.3	16
13	Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Haematologica, 2019, 104, e38-e41.	3.5	16
14	Screening and monitoring of the <i>BTK</i> ^{C481S} mutation in a realâ€world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. British Journal of Haematology, 2021, 194, 355-364.	2.5	13
15	Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. Pathology and Oncology Research, 2017, 23, 165-171.	1.9	5
16	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. Pathology, 2022, 54, 95-103.	0.6	5
17	Ventricular Tachycardia Caused by Ibrutinib. Journal of Emergency Medicine, 2017, 53, e27.	0.7	2